Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

被引：28

作者：

Rossi, Ernesto ^{[1
]}

Maiorano, Brigida Anna ^{[1
]}

Pagliara, Monica Maria ^{[2
]}

Sammarco, Maria Grazia ^{[2
]}

Dosa, Tommaso ^{[1
]}

Martini, Maurizio ^{[3
]}

Rindi, Guido ^{[3
]}

Bria, Emilio ^{[1
]}

Blasi, Maria Antonietta ^{[2
]}

Tortora, Giampaolo ^{[1
]}

Schinzari, Giovanni ^{[1
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Med Oncol, Rome, Italy

[2] Fdn Policlin Univ A Gemelli IRCCS, Ophtalmol, Rome, Italy

[3] Fdn Policlin Univ A Gemelli IRCCS, Pathol, Rome, Italy

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

BRAF; MEK; target therapy; conjunctival; melanoma; NRAS MUTATIONS; MEK INHIBITION; HARBOR BRAF; SURVIVAL; PHASE-3;

D O I：

10.3389/fonc.2019.00232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.

引用

页数：5

共 50 条

[31] Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma
Hennemann, Aymeric
Puzenat, Eve
Decreuse, Marion
Vuillier, Fabrice
Nardin, Charlee
Aubin, Francois
MELANOMA RESEARCH, 2024, 34 (03) : 280 - 282
[32] Multiple BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF-Mutant Melanoma
Carrera, Cristina
Puig-Butille, Joan A.
Tell-Marti, Gemma
Garcia, Adriana
Badenas, Celia
Alos, Llucia
Puig, Susana
Malvehy, Josep
JAMA DERMATOLOGY, 2015, 151 (05) : 544 - 548
[33] Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma
Cebollero, Ana
Puertolas, Teresa
Pajares, Isabel
Calera, Lourdes
Anton, Antonio
MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (04) : 458 - 462
[34] Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V.
Hauschild, A.
Santinami, M.
Atkinson, V.
Mandala, M.
Chiarion-Sileni, V.
Larkin, J.
Nyakas, M.
Dutriaux, C.
Haydon, A.
Robert, C.
Mortier, L.
Schachter, J.
Schadendorf, D.
Lesimple, T.
Plummer, R.
Ji, R.
Zhang, P.
Mookerjee, B.
Legos, J.
Kefford, R.
Dummer, R.
Kirkwood, J. M.
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1813 - 1823
[35] First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma
Kim, Chang Gon
Kim, Miso
Hwang, Jieon
Kim, Seung Tae
Jung, Minkyu
Kim, Kyoo Hyun
Kim, Kyung Hwan
Chang, Jee Suk
Koom, Woong Sub
Roh, Mi Ryung
Chung, Kee Yang
Kim, Tae Min
Kim, Sang Kyum
Lee, Jeeyun
Shin, Sang Joon
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (05) : 989 - 996
[36] Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Subbiah, Vivek
Kreitman, Robert J.
Wainberg, Zev A.
Cho, Jae Yong
Schellens, Jan H. M.
Soria, Jean Charles
Wen, Patrick Y.
Zielinski, Christoph
Cabanillas, Maria E.
Urbanowitz, Gladys
Mookerjee, Bijoyesh
Wang, Dazhe
Rangwala, Fatima
Keam, Bhumsuk
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (01) : 7 - +
[37] Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
Planchard, David
Besse, Benjamin
Groen, Harry J. M.
Hashemi, Sayed M. S.
Mazieres, Julien
Kim, Tae Min
Quoix, Elisabeth
Souquet, Pierre-Jean
Barlesi, Fabrice
Baik, Christina
Villaruz, Liza C.
Kelly, Ronan J.
Zhang, Shirong
Tan, Monique
Gasal, Eduard
Santarpia, Libero
Johnson, Bruce E.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 103 - 115
[38] Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
Aglietta, Massimo
Chiarion-Sileni, Vanna
Fava, Paolo
Guidoboni, Massimo
Depenni, Roberta
Minisini, Alessandro
Consoli, Francesca
Ascierto, Paolo
Rinaldi, Gaetana
Banzi, Maria
Marconcini, Riccardo
Gueli, Rossana
Ferraresi, Virginia
Tucci, Marco
Tonini, Giuseppe
Lo Re, Giovanni
Guida, Michele
Del Vecchio, Michele
Marcon, Ilaria Gioia
Queirolo, Paola
TARGETED ONCOLOGY, 2021, 16 (06) : 789 - 799
[39] Combined BRAF and MEK Inhibition with Dabrafenib and Trametinib in BRAF V600-mutant colorectal cancer
Loir, E.
Cochereau, D.
ONCOLOGIE, 2016, 18 (9-10) : 565 - 566
[40] Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Corcoran, Ryan B.
Atreya, Chloe E.
Falchook, Gerald S.
Kwak, Eunice L.
Ryan, David P.
Bendell, Johanna C.
Hamid, Omid
Messersmith, Wells A.
Daud, Adil
Kurzrock, Razelle
Pierobon, Mariaelena
Sun, Peng
Cunningham, Elizabeth
Little, Shonda
Orford, Keith
Motwani, Monica
Bai, Yuchen
Patel, Kiran
Venook, Alan P.
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4023 - +

← 1 2 3 4 5 →